Lijuan Huang
About Lijuan Huang
Lijuan Huang serves as the Chief Financial Officer at Ligand Pharmaceuticals, where she has worked since 2020. She has a background in accounting and finance, with previous roles at Deloitte, Neurocrine Biosciences, and Vertex Pharmaceuticals.
Current Role at Ligand Pharmaceuticals
Lijuan Huang serves as the Chief Financial Officer at Ligand Pharmaceuticals, a position she has held since 2020. In this role, she is responsible for overseeing the financial operations of the company, which focuses on drug discovery, early-stage drug development, product reformulation, and strategic partnerships. Her leadership contributes to the company's efforts in creating value for shareholders through a diversified portfolio of biotechnology and pharmaceutical product revenue streams.
Previous Experience in Finance
Prior to her current role, Lijuan Huang worked at Neurocrine Biosciences as a Financial Reporting Manager from 2015 to 2020. In this capacity, she managed financial reporting processes and ensured compliance with regulatory requirements. Before that, she was employed at Vertex Pharmaceuticals as a Senior Accountant from 2011 to 2015, where she contributed to financial analysis and reporting in the Houston, Texas Area and San Francisco, CA. Her career began at Deloitte, where she worked as a Corporate Accountant from 2008 to 2011.
Educational Background
Lijuan Huang holds a Master of Science (M.S.) in Business/Managerial Economics from the University of California, Davis. She also earned a Bachelor of Science in Accounting from Shanghai University of Finance and Economics, where she studied Accounting and Finance. Her educational background provides a strong foundation for her roles in financial management and reporting within the biotechnology and pharmaceutical sectors.
Professional Interests and Focus
Lijuan Huang has a keen interest in connecting with professionals from various fields to facilitate mutual learning and growth. Her professional focus is on creating shareholder value through effective financial strategies and a diversified product portfolio. She emphasizes the importance of collaboration and knowledge exchange in her work, which aligns with her role in the dynamic biotechnology and pharmaceutical industries.